Lapatinib Completed Phase 1 / 2 Trials for Cancer, Breast Treatment

Indications	Status	Purpose	Phase
DBCOND0054116 (Cancer, Breast)	Completed	Treatment	1 / 2

clinicaltrials.gov Identifier	Title	Drugs
NCT00085020	GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu	Lapatinib (DB01259) Trastuzumab (DB00072)
NCT00379509	Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer	Lapatinib (DB01259)
NCT00753207	Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30	Lapatinib (DB01259) Epirubicin (DB00445)
NCT00632489	LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients	Lapatinib (DB01259) Panobinostat (DB06603) Capecitabine (DB01101)
NCT00513058	Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer	Vinorelbine (DB00361) Lapatinib (DB01259)
NCT01133912	Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT)	Lapatinib (DB01259) Gemcitabine (DB00441) Paclitaxel (DB01229)
NCT00316875	Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer	Lapatinib (DB01259) Doxorubicin (DB00997)